ReviewReviews in endocrine & metabolic disorders2024
The genetics of Graves' disease.
Review in Reviews in endocrine & metabolic disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Role of interleukin 17 and T helper cells 17 cells as a new immune target and signalling in the pathogenesis and treatment of autoimmune thyroid diseases.Annals of medicine · 2025Pooled it
- Genetic correlation and causal relationships between autoimmune thyroid disease and major depressive disorders.Acta neuropsychiatrica · 2025Pooled it
- Differential analysis of gut microbiota and metabolites in patients with Graves' disease and combined Helicobacter pylori infection.BMC endocrine disorders · 2026Article
- HLA Class I Haplotype in Glutamic Acid Decarboxylase Antibody-Associated Neurological Disease.European journal of neurology · 2026Article
- Sex-Based Differences in Noncommunicable Diseases in Older Adults: Raising the Profile of Older Females.Journal of the American Geriatrics Society · 2026Article
- Severe agranulocytosis in patient with Graves' disease on second exposure to carbimazole.Endocrinology, diabetes & metabolism case reports · 2026Article
- Abnormal Elevation of the Expression of Costimulatory Molecule CD226 in Graves' DiseaseEndocrine, metabolic & immune disorders drug targets · 2026Article
- ICPi-Induced Graves' Disease with Pre-existing Autoimmune Thyroid Disorders: A Case Report and Literature Review.Endocrine, metabolic & immune disorders drug targets · 2026Review
- The therapeutic revolution in thyroid eye disease: from orbital radiotherapy to teprotumumab and AI.Frontiers in medicine · 2026Review
- Pathogenic and Regulatory Roles of Fibrinolytic Factors in Autoimmune Diseases.Current issues in molecular biology · 2025Review
- Hub genes and key pathways of Graves' disease: bioinformatics analysis and validation.Hormones (Athens, Greece) · 2025Article
- Exploring thyroid eye disease in Brazil: insights from a single-center study.Archives of endocrinology and metabolism · 2025Article
- Myasthenia gravis complicated by Graves' disease: a case report.Journal of medical case reports · 2025Article
- Thyroid-Targeted Nano-Bombs Empower HIFU for Graves' Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Growth arrest and DNA damage-inducible 45: a new player on inflammatory diseases.Frontiers in immunology · 2025Review
- Exploring antigenic variation in autoimmune endocrinopathy.Frontiers in immunology · 2025Review
- Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms.Frontiers in endocrinology · 2025Review
- The genomic bases of atrial fibrillation in an Ecuadorian patient: a case report.Frontiers in cardiovascular medicine · 2025Article
- Th17-associated cytokine gene hypomethylation reflects epigenetic dysregulation in graves' disease.Frontiers in immunology · 2025Article
- COVID-19 vaccine-induced autoimmune hyperthyroidism: Graves' disease.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Graves' disease (GD) is the commonest cause of hyperthyroidism and has a strong female preponderance. Everyday clinical practice suggests strong aggregation within families and twin studies demonstrate that genetic factors account for 60-80% of risk of developing GD. In this review, we collate numerous genetic studies and outline the discoveries over the years, starting with historic candidate gene studies and then exploring more recent genome-wide linkage and association studies, which have involved substantial cohorts of East Asian patients as well as those of European descent. Variants in genes including HLA, CTLA4, and PTPN22 have been shown to have substantial individual effects on disease susceptibility. In addition, we examine emerging evidence concerning the possibility that genetic variants may correlate with relevant clinical phenotypes including age of onset of GD, severity of thyrotoxicosis, goitre size and relapse of hyperthyroidism following antithyroid drug therapy, as well as thyroid eye disease. This review supports the inheritance of GD as a complex genetic trait, with a growing number of more than 80 susceptibility loci identified so far. Future implementation of more targeted clinical therapies requires larger studies investigating the influence of these genetic variants on the various phenotypes and different outcomes of conventional treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.